| Literature DB >> 31660357 |
Lina Saeed1,2, Robert J Weber1, Sarah B Puryear1,3, Eman Bahrani1,2, Michael J Peluso1,3, Jennifer M Babik1,3, Anna Haemel1,2, Sarah J Coates1,2.
Abstract
Disseminated sporotrichosis may present with inflammatory arthritis and cutaneous ulcerations that mimic noninfectious skin conditions such as pyoderma gangreonsum (PG). Sporotrichosis must therefore be ruled out before administering immunosuppressive agents for PG. Furthermore, dimorphic fungi such as sporotrichosis may grow as yeast in bacterial cultures, even before fungal cultures become positive. We present a case of disseminated cutaneous and osteoarticular sporotrichosis mimicking PG and describe the differential diagnosis and the diagnostic and treatment approach to this condition.Entities:
Keywords: Sporothrix; United States of America; deep fungal infection; disseminated fungal infection; septic arthritis; ulcer
Year: 2019 PMID: 31660357 PMCID: PMC6786506 DOI: 10.1093/ofid/ofz395
Source DB: PubMed Journal: Open Forum Infect Dis ISSN: 2328-8957 Impact factor: 3.835
Figure 1. Skin lesions. A, Indurated, erythematous subcutaneous nodule with overlying scale on the right upper arm, representative of the early stages of evolution of these skin lesions. B, Left wrist exam, showing ulcerations with violaceous to erythematous undermined borders and a fibrinous base.
Figure 2. A, Right upper extremity lesion after second debridement surgery. Significant full-thickness ulcer with erythematous, undermined borders covers most of forearm. Yellow material is a combination of fibrinous debris and gel wound dressing. B, Biopsy sample demonstrating PAS-D staining of yeast surrounding subcutaneous arterioles.
Figure 3. Culture findings. A, Sporothrix schenkii is a dimorphic fungus that grows as a mold at 30°C and as a yeast at 37°C. Culture specimens from surgical debridement are shown. B, Speciation of the mold was confirmed by microscopic examination, demonstrating hyphae and flower-like conidia.
Case Reports of Disseminated Sporotrichosis in Immunocompetent Individuals
| Publication | Location | Age/Sex | Sites Involved | Risk Factor(s) | Treatment Regimen | Outcome |
|---|---|---|---|---|---|---|
| Campos-Macias et al. (2006) [ | Japan | 74/M | Skin (multiple sites) | None identified | Itraconazole 400 mg/d × 4 mo, then stopped prematurely | Final outcome not provided |
| Yap (2011) [ | Malaysia | 70/F | Skin (multiple sites) | Gardening | Amphotericin 0.7 mg/kg/d for 2 wk, followed by itraconazole 400 mg/d for 8 mo | Resolution |
| Ribeiro et al. (2015) [ | Brazil | 5/M | Skin (multiple sites) | None identified | Amphotericin (dose unknown) for 2 wk, followed by itraconazole (dose unknown) for 45 d | Resolution |
| Hassan et al. (2016) [ | USA | 56/M | Skin | Farmer | Liposomal amphotericin 3 mg/kg/d for 1 mo; discharged on itraconazole | Patient lost to follow-up |
| Hessler et al. (2017) [ | California, USA | CNS – chronic meningitis | Construction worker | Itraconazole for 12 mo | Resolution |
Abbreviations: CNS, central nervous system; DM, diabetes mellitus.
Case Reports of Disseminated Sporotrichosis Mimicking Pyoderma Gangrenosum, in Addition to Those Reported in Case Series From Byrd et al. (2001) [17] and Weenig et al. (2002) [9]
| Publication | Location | Age/ Sex | Host Features and Risk Factor(s) | Sites Involved | Treatments Received for Suspected PG | Time to Correct Diagnosis | Treatment Regimen | Outcome |
|---|---|---|---|---|---|---|---|---|
| Charles et al. (2017) [ | Michigan, USA | 57/F | Immunocompetent | Skin (multiple sites) | Methylprednisolone, prednisone, clobetasol | 10 mo | Itraconazole 200 mg/d for 3 mo, then 200 mg twice daily due to poor response | Improved |
| Lima et al. (2017) [ | Brazil | 39/F | Immunocompetent | Skin (multiple sites) | Systemic corticosteroids, infliximab (which triggered dissemination) | >24 mo | Liposomal amphotericin 400 mg/d for 6 wk, followed by itraconazole 400 mg/d for 12 mo | Resolution |
| Takazawa et al. (2018) [ | Japan | 47/M | History of ulcerative colitis on mesalamine | Skin (single site) | Topical steroid ointment | 4 mo | Potassium iodide 500 mg for 2 wk, followed by 1000 mg and local heat therapy for 3 wk | Resolution |
Abbreviations: PG, pyoderma gangreonsum; PMH,